黑色素瘤个体化mRNA疫苗研究进展如何？

IF 5.2 3区医学 Q1 IMMUNOLOGY

Vaccines Pub Date : 2025-09-21 DOI:10.3390/vaccines13090986

Ioanna Gazouli, Dimitrios Bafaloukos, Christos Koutserimpas, George Samonis

{"title":"黑色素瘤个体化mRNA疫苗研究进展如何？","authors":"Ioanna Gazouli, Dimitrios Bafaloukos, Christos Koutserimpas, George Samonis","doi":"10.3390/vaccines13090986","DOIUrl":null,"url":null,"abstract":"Immunotherapy, consisting mainly of immune checkpoint inhibitors, has been successfully employed in the treatment of early and advanced-stage melanoma for more than ten years. Personalized mRNA vaccines represent the next evolutionary step, offering patients a treatment unique to them and their tumor, whilst putting recent, significant technological and scientific advances into practice. Clinical and preclinical data about mRNA vaccines are now emerging, further encouraging research and spreading enthusiasm among patients and physicians. Nonetheless, a lot remains to be discovered about mRNA vaccines' mechanisms of action, their actual effect on the immune cells of the patient, and successful mRNA delivery to the host.","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"13 9","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2025-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474233/pdf/","citationCount":"0","resultStr":"{\"title\":\"Individualized mRNA Vaccines in Melanoma-Where Do We Stand?\",\"authors\":\"Ioanna Gazouli, Dimitrios Bafaloukos, Christos Koutserimpas, George Samonis\",\"doi\":\"10.3390/vaccines13090986\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Immunotherapy, consisting mainly of immune checkpoint inhibitors, has been successfully employed in the treatment of early and advanced-stage melanoma for more than ten years. Personalized mRNA vaccines represent the next evolutionary step, offering patients a treatment unique to them and their tumor, whilst putting recent, significant technological and scientific advances into practice. Clinical and preclinical data about mRNA vaccines are now emerging, further encouraging research and spreading enthusiasm among patients and physicians. Nonetheless, a lot remains to be discovered about mRNA vaccines' mechanisms of action, their actual effect on the immune cells of the patient, and successful mRNA delivery to the host.\",\"PeriodicalId\":23634,\"journal\":{\"name\":\"Vaccines\",\"volume\":\"13 9\",\"pages\":\"\"},\"PeriodicalIF\":5.2000,\"publicationDate\":\"2025-09-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474233/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vaccines\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/vaccines13090986\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/vaccines13090986","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

免疫疗法，主要由免疫检查点抑制剂组成，已经成功地用于治疗早期和晚期黑色素瘤超过十年。个性化mRNA疫苗代表了下一个进化步骤，为患者及其肿瘤提供独特的治疗方法，同时将最新的重大技术和科学进步付诸实践。关于mRNA疫苗的临床和临床前数据正在出现，进一步鼓励了研究并在患者和医生中传播了热情。尽管如此，关于mRNA疫苗的作用机制、对患者免疫细胞的实际影响以及mRNA成功递送到宿主，仍有很多有待发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Individualized mRNA Vaccines in Melanoma-Where Do We Stand?

Immunotherapy, consisting mainly of immune checkpoint inhibitors, has been successfully employed in the treatment of early and advanced-stage melanoma for more than ten years. Personalized mRNA vaccines represent the next evolutionary step, offering patients a treatment unique to them and their tumor, whilst putting recent, significant technological and scientific advances into practice. Clinical and preclinical data about mRNA vaccines are now emerging, further encouraging research and spreading enthusiasm among patients and physicians. Nonetheless, a lot remains to be discovered about mRNA vaccines' mechanisms of action, their actual effect on the immune cells of the patient, and successful mRNA delivery to the host.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Vaccines Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

8.90

自引率

16.70%

发文量

1853

审稿时长

18.06 days

期刊介绍： Vaccines (ISSN 2076-393X) is an international, peer-reviewed open access journal focused on laboratory and clinical vaccine research, utilization and immunization. Vaccines publishes high quality reviews, regular research papers, communications and case reports.